Piperazinyl compounds

Details Piperazinyl compounds Piperazinyl compounds

2008-05-30

2010-10-19

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

07816530

ABSTRACT:
Disclosed are new dihydropteridinones of general formula (I)wherein the groups L and R1-R5have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

REFERENCES:
patent: 4957922 (1990-09-01), Lammens et al.
patent: 5167949 (1992-12-01), Ferrand et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
patent: 5698556 (1997-12-01), Chan
patent: 6174895 (2001-01-01), Kleinman
patent: 6444677 (2002-09-01), Ikeda et al.
patent: 6605255 (2003-08-01), Kroll et al.
patent: 6806272 (2004-10-01), Bauer et al.
patent: 6861422 (2005-03-01), Hoffmann et al.
patent: 7238807 (2007-07-01), Duran et al.
patent: 7241889 (2007-07-01), Hoffmann et al.
patent: 7332491 (2008-02-01), Grauert et al.
patent: 7371753 (2008-05-01), Stadtmueller et al.
patent: 7414053 (2008-08-01), Grauert et al.
patent: 7439358 (2008-10-01), Linz et al.
patent: 7547780 (2009-06-01), Grauert et al.
patent: 2002/0183292 (2002-12-01), Pairet et al.
patent: 2002/0183293 (2002-12-01), Banerjee et al.
patent: 2003/0130286 (2003-07-01), Denny et al.
patent: 2004/0029885 (2004-02-01), Bauer et al.
patent: 2004/0147524 (2004-07-01), Bauer et al.
patent: 2004/0176380 (2004-09-01), Hoffmann et al.
patent: 2005/0014760 (2005-01-01), Hoffmann et al.
patent: 2005/0014761 (2005-01-01), Hoffmann et al.
patent: 2005/0148501 (2005-07-01), Palmer et al.
patent: 2005/0159414 (2005-07-01), Nickolaus et al.
patent: 2005/0165010 (2005-07-01), Nickolaus et al.
patent: 2006/0004014 (2006-01-01), Hoffmann et al.
patent: 2006/0009457 (2006-01-01), Hoffmann et al.
patent: 2006/0025411 (2006-02-01), Hoffmann et al.
patent: 2006/0035902 (2006-02-01), Linz et al.
patent: 2006/0035903 (2006-02-01), Mohr et al.
patent: 2006/0046989 (2006-03-01), Grauert et al.
patent: 2006/0047118 (2006-03-01), Stadtmueller et al.
patent: 2006/0052383 (2006-03-01), Grauert et al.
patent: 2006/0058311 (2006-03-01), Munzert et al.
patent: 2006/0074088 (2006-04-01), Munzert et al.
patent: 2006/0079503 (2006-04-01), Schwede et al.
patent: 2007/0208027 (2007-09-01), Duran et al.
patent: 2007/0213528 (2007-09-01), Duran et al.
patent: 2007/0213529 (2007-09-01), Duran et al.
patent: 2007/0213530 (2007-09-01), Duran et al.
patent: 2007/0213531 (2007-09-01), Duran et al.
patent: 2007/0213534 (2007-09-01), Duran et al.
patent: 2007/0219369 (2007-09-01), Duran et al.
patent: 2008/0108812 (2008-05-01), Grauert et al.
patent: 2008/0113992 (2008-05-01), Grauert et al.
patent: 2008/0171747 (2008-07-01), Hoffman et al.
patent: 2008/0177066 (2008-07-01), Linz et al.
patent: 2008/0194818 (2008-08-01), Grauert et al.
patent: 2008/0221099 (2008-09-01), Munzert et al.
patent: 2008/0293944 (2008-11-01), Hoffmann et al.
patent: 2008/0319190 (2008-12-01), Grauert et al.
patent: 2008/0319192 (2008-12-01), Grauert et al.
patent: 2008/0319193 (2008-12-01), Grauert et al.
patent: 2009/0018333 (2009-01-01), Grauert et al.
patent: 2009/0030004 (2009-01-01), Linz et al.
patent: 2009/0124628 (2009-05-01), Hoffmann et al.
patent: 2009/0143379 (2009-06-01), Mohr et al.
patent: 2458699 (2003-03-01), None
patent: 2517020 (2004-09-01), None
patent: 2517010 (2004-11-01), None
patent: 2576290 (2006-02-01), None
patent: 143478 (1985-06-01), None
patent: 347146 (1989-12-01), None
patent: 399856 (1990-11-01), None
patent: 429149 (1991-05-01), None
patent: 2287583 (2007-12-01), None
patent: 9609045 (1996-03-01), None
patent: 9634867 (1996-11-01), None
patent: 9636597 (1996-11-01), None
patent: 9811893 (1998-03-01), None
patent: 0119825 (2001-03-01), None
patent: 0170741 (2001-09-01), None
patent: 0178732 (2001-10-01), None
patent: 02057261 (2002-07-01), None
patent: 02076954 (2002-10-01), None
patent: 02076985 (2002-10-01), None
patent: 03020722 (2003-03-01), None
patent: 03093249 (2003-11-01), None
patent: 04014899 (2004-02-01), None
patent: 04076454 (2004-09-01), None
patent: 04093848 (2004-11-01), None
patent: 05067935 (2005-07-01), None
patent: 06/018182 (2006-02-01), None
patent: 06/018221 (2006-02-01), None
patent: 06018185 (2006-02-01), None
patent: 06018220 (2006-02-01), None
patent: 06018221 (2006-02-01), None
patent: 06021378 (2006-03-01), None
patent: 07090844 (2007-08-01), None
patent: 09019205 (2009-02-01), None
Kimball et al.; Chapter 14, Cell Cycle Kinases and Checkpoint Regulation in Cancer; Annual Reports in Medicinal Chemistry—35; pp. 139-148.
Savelli et al.; Heterotricyclic System Part II—Synthesis of new pyrido [1′,2′:4,5] pyrazine [3,2-d] pyrimidines; Istituto di Scienze Farmaceutiche; Universita di Genova; Viale Benedetto XV, 3-16:32 Genova; pp. 309-312.
Ferrand et al.; Synthesis and potential antiallergic activity of new pteridinones and related compounds; European Journal Medicinal Chemistry; 1996; vol. 31; No. 4; pp. 273-280.
Arnold; Collaboration to Play Key Role in NCI's Future, Director Says; Journal of the National Cancer Institute; Jun. 5, 2002; pp. 790-792; vol. 94; No. 11 <http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;94/11/790>.
Webster's Comprehensive Dictionary, 1996, pp. 1013-1014.
Wikipedia. “Melting Point”, Jan. 17, 2007.
Wolf, D. E. et al., “The structure of rhizopterin”. Contribution from the Research Labs of Merck and Co. Inc. Nov. 1947, Journal of American Chem. Soc., vol. 69, pp. 2753-2759. XP002352205.
ACPS Meeting, Background Information. “Scientific considerations of plymorphism in pharmaceutical solids: abbreviated new drug applications”. Oct. 2002.
Ahlenius, T. List of cardiovascular disorder/diseases. Ahlenius, Karolinska Institutet. Stockholm, Sweden. Cardiovascular Diseases, p. 1-34, Apr. 2007.
Ahmad, N. “Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer”. The FASEB Journal. 2004, 18:5-7. Dept of Dermatology, Univ. Wisconsin, pp. 5-7.
BBC News/Health, Killer Breast Cancern Therapy Hope, www.newsvote.bbc/co./uk, downloaded Mar. 26, 2009.
Bennett, J.C., et al., “Textbook of Medicine”, Part XIV, Oncology, 1997.
Blain, S. W. et al., “Differential interaction of the cyclin-dependent kinase (Cdk) Inhibitor p27KIP with cyclin A-Cdk2 and cyclin D2-Cdk4”. The Journal of Biological Chemistry, vol. 272, No. 41, Issue Oct. 10, 1997, pp. 25862-25872.
Dipolar aprotic solvent. Exhibit A, IUPAC Compendium of Chemical Terminology, 2nd Edition, 1997.
Doerwald, F.Z. Book Wiley-VCH Verlag GmbH & Co. KGaA, “Side reactions in organice synthesis: A Guide to Successful Synthesis Design”. 2005.
Eurasian Opinion, Appln No. 2007/00389/28, Maly Slatoustinsky per., d.10, kv.15, 101000 Moscow, Russia, “EVROMARKPAT”, 2007.
Ghandi, L., et al., “An Open-Label Phase II Trial of the PLK Inhibitor BI 2536 in Patients with Sensitive Relapse Small Cell Lung Cancer”. ASCO Meeting 2009.
Giron, G. “Thernal analysis and calorimetric methods in the characterization of plymorphs and solvates”. Thermochimica Acta 248, 1995, pp. 1-59.
Goodman-Gilman's “The Pharmacological Basis of Therapeutics”. Ninth edition, 1996, pp. 1225-1271.
Ito, Y., et al., “Polo-like kinase 1 (PLK) expression is associated with cell proliferative activity and cdc2 expression in malignant-lymphoma of the thyroid”. Anticancer Research, 2004, vol. 24, No. 1, pp. 259-263.
Jaworska, J., et al., “Review of methods for assessing the applicability domains of SARS and QSARS”. Sponsor: The European Commission—Joint Research Ctr., Institute for Health and Consumer Protection—ECVAM, Italy, 2004.
Kashima, M. K. et al., “Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas”. NCBI, PubMed, 2005.
Leukemia & Lymphoma Society—Disease Information-Lymphoma. www.leukemia-lymphoma.org/all—page?item—id-7030, downloaded Mar. 26, 2009.
Leukemia & Lymphoma Society—Disease Information. www.leukemia-lymphoma.org/all—page?item—id-7026, downloaded Mar. 26, 20

Affiliated with

Also associated with

Rating

Piperazinyl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazinyl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4186786